Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
Yazar
Barrios, C. H.
Herbst, R. S.
de Marinis, F.
Giaccone, G.
Reinmuth, N.
Vergnenegre, A.
Morise, M.
Felip, E.
Andric, Z.
Geater, S.
Ozguroglu, M.
Mocci, S.
McCleland, M.
Zou, W.
Enquist, I.
Komatsubara, K.
Deng, Y.
Kuriki, H.
Spigel, D. R.
Jassem, J.
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]